{"disease":{"id":"chronic-hepatitis-c","name":"Chronic hepatitis C","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":17,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"eltrombopag","indication_name":"Thrombocytopenia in Chronic Hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"sovaldi","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sovaldi","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cereblon isoform 4, Genome polyprotein, NS5","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"beclabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BECLABUVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"boceprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victrelis","generic_name":"BOCEPREVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Chymase","drug_class":"Hepatitis C Virus NS3/4A Protease Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"grazoprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"GRAZOPREVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Zepatier blocks the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"daklinza","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daklinza","company_name":"Genuine Research Center, Egypt","drug_phase":"phase_1","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Genome polyprotein, Nonstructural protein 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"peginterferon","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pegasys","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"ritonavir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"elbasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"ELBASVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zepatier works by blocking the NS5A protein of the hepatitis C virus, preventing it from replicating."},{"drug_id":"daclatasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daklinza","generic_name":"DACLATASVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Hepatitis C Virus NS5A Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"glecaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mavyret","generic_name":"GLECAPREVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"asunaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunvepra","generic_name":"ASUNAPREVIR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dasabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viekira Pak (Copackaged)","generic_name":"DASABUVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Protein cereblon","drug_class":"Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"norvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ribavarin","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ribavarin","company_name":"Charles University, Czech Republic","drug_phase":"discontinued","molecular_target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (genotype 1)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (treatment-naïve and treatment-experienced)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (Japanese population)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odv-25-mg","indication_name":"Chronic Hepatitis C (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODV 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":18,"totalPipeline":5},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT07258251","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"The Task Force for Global Health","has_results":false},{"nct_id":"NCT05181956","title":"Testing and Epidemiology of Delta Hepatitis","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Asian Pacific Liver Center at Coalition of Inclusive Medicine","has_results":false},{"nct_id":"NCT05813691","title":"Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative.","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05062967","title":"Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":3257,"lead_sponsor_name":"Maimónides Biomedical Research Institute of Córdoba","has_results":false},{"nct_id":"NCT02629172","title":"Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1","phase":"","overall_status":"COMPLETED","enrollment_count":3043,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02250001","title":"Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C","phase":"","overall_status":"COMPLETED","enrollment_count":2974,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07298577","title":"Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07476703","title":"Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Danderyd Hospital","has_results":false},{"nct_id":"NCT02578693","title":"Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":1210,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT06874127","title":"Non-Invasive Model for Fibrosis Regression in HBV Patients","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03693586","title":"Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Hospital General de Mexico","has_results":false},{"nct_id":"NCT04301882","title":"An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT05766449","title":"Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT04071353","title":"Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT05630807","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":981,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT06906016","title":"New HBV Infection Biomarkers: Clinical Characterization and Impact on Management","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05630820","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":857,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03941821","title":"Glecaprevir/Pibrentasvir Real-world Study in China","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04166266","title":"National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT06373198","title":"Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hospital El Cruce","has_results":false},{"nct_id":"NCT03993925","title":"Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04690972","title":"\"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases\".","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT02618928","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","phase":"","overall_status":"COMPLETED","enrollment_count":735,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02243293","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":694,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05792878","title":"Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT06072287","title":"The Living With a Long-Term Condition Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT02581189","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":565,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02807402","title":"Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania","phase":"","overall_status":"COMPLETED","enrollment_count":522,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03977857","title":"Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-Chronic","phase":"","overall_status":"COMPLETED","enrollment_count":486,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT02615145","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)","phase":"","overall_status":"COMPLETED","enrollment_count":472,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT01866930","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":453,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02945228","title":"Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2","phase":"","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04135235","title":"Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B","phase":"","overall_status":"UNKNOWN","enrollment_count":440,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT02105467","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":421,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04030039","title":"Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention","phase":"","overall_status":"UNKNOWN","enrollment_count":420,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT02640547","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C","phase":"","overall_status":"COMPLETED","enrollment_count":394,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04330508","title":"Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial","phase":"","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT05117541","title":"Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":365,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT06544551","title":"Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Beijing Kawin Technology Share-Holding Co., Ltd.","has_results":false},{"nct_id":"NCT01455090","title":"Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01939197","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02581163","title":"Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02105688","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}